Navigation Links
'Enormous Progress' in Reducing Cancer Does Not Include Lung Cancer
Date:2/25/2008

WASHINGTON, Feb. 25 /PRNewswire-USNewswire/ -- Lung Cancer Alliance (LCA) cautioned today that recently released cancer statistics indicate that lung cancer continues to kill more people each year than all the other major cancers combined.

Last week, in issuing its annual review of government statistics entitled Cancer Facts and Figures for 2008, the American Cancer Society cited the "enormous progress that has been made against cancer over the past 15 years."

Laurie Fenton Ambrose, LCA President & CEO said, "Sadly this is not true for lung cancer, which is still the biggest cancer killer and its 5 year survival rate is still only 15 percent."

In the 2003 report, ACS started using the 2000 census for its age adjusted statistical analysis.

Since that time, the incidence rate for lung cancer in men rose from 86 new cases per every 100,000 of population to 89, and incidence rates for women went from 51.4 to 55.2.

While the death rates for men have gone down in that time period, death rates for women continue to rise.

In its 2005 report, ACS claimed that lung cancer in women had "reached a plateau." That was changed to "reaching a plateau" in the 2006 and 2007 reports, and changed again to "approaching a plateau" in the just released 2008 report as the number of women being diagnosed and dying of lung cancer continued to climb.

"There is no way to put a happy face on these numbers which will continue to go up until we fund lung cancer research with a sense of urgency and at a level commensurate with its public health impact," Fenton Ambrose said.

In research dollars per death, lung cancer is receiving a fraction of the amounts given to breast, prostate and colon cancers. The five-year survival rate for breast cancer now stands at 88 percent, prostate cancer 99 percent and colon cancer 65 percent while lung cancer remains at 15 percent.

In addition, ACS credits screening as a major component in achieving these high survival rates and recommends annual mammograms for all women over 40 even though randomized controlled trials have not ended the debate about mammograms for women under 50.

PSA testing for prostate cancer and CT scans for lung cancer are currently undergoing randomized controlled trials and the US government gives both screening tests the same "I" rating: insufficient evidence to recommend for or against.

However, while mute on lung cancer screening, ACS strongly supports offering a PSA test to all men over 50 and urges that they be given information on prostate cancer screening "so they can make an informed decision."

"Why shouldn't those at risk for lung cancer be treated the same way and be allowed to make an informed decision with their doctors about the risks and benefits of C scans. There should not be such a double standard," Fenton-Ambrose stated.

Lung Cancer Alliance (http://www.lungcanceralliance.org) is the only national non-profit organization dedicated solely to patient support and advocacy for those living with or at risk for lung cancer. LCA is committed to leading the movement to reverse decades of stigma and neglect by empowering those with or at risk for the disease, elevating awareness and changing health policy.


'/>"/>
SOURCE Lung Cancer Alliance
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. L.A. Playwright Creates an Enormous Wave with His New Book, Touch the Ocean
2. New MRI finding sheds light on multiple sclerosis disease progressio
3. Brain Lesions Predict MS Progression
4. Pregnancy may slow -- not accelerate -- progression to AIDS
5. STAAR Surgical Reports Operational Progress
6. Progression of SIV infection in monkeys raises
7. Study makes progress in zoning in on biomarkers for better colon cancer treatment
8. Chemotherapy with gemcitabine delays progression of operable pancreatic cancer
9. Limiting refined carbohydrates may stall AMD progression
10. World Bank Group Report on Malaria in Africa Highlights Progress Towards Goal of Significantly Reducing Malaria Deaths
11. New Data Suggests Progression of Disability at Two Years Predicts Multiple Sclerosis (MS) Disability Progression at Eight Years
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... ... The Patient Advocacy Community of The Beryl Institute presented Eve DeVaro, Director, Patient ... Award in recognition of her extraordinary contributions to the field of patient advocacy ... Institute’s annual Patient Experience Conference on March 20 in Denver, Colorado. ...
(Date:4/21/2017)... Hong Kong (PRWEB) , ... April 21, 2017 , ... ... Printing (U3DP), the first 3D printing facility among higher education institutions in Hong Kong ... 3D printing, in terms of the range and quantity of facilities in Hong Kong. ...
(Date:4/21/2017)... ... April 21, 2017 , ... ... AWARE: A Week of Addiction and Recovery Education, from April 24 to April ... preventing substance use disorders. , The mission of AWARE is to instill ...
(Date:4/21/2017)... , ... April 21, 2017 , ... ... announced an exciting new partnership with the highly regarded and well renowned Asian ... highly innovative, myTAP & myTAP PAP Nasal Pillow Mask, and will stabilize and ...
(Date:4/21/2017)... Worcestershire, UK (PRWEB) , ... April 21, 2017 ... ... Award for Enterprise in the category of International Trade, the UK’s most prestigious ... in international trade, which represents 95% of total revenues and has grown by ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... April 20, 2017 Research and ... Biosimilar Pipeline and Market Prospects: Addressing Production Complexities Through ... their offering. ... "Global Biosimilar Pipeline and Market Prospects: Overcoming Production ... an in-depth assessment of the current trends in the ...
(Date:4/20/2017)... , April 20, 2017   ZappRx, Inc ., ... specialty drug prescribing process, today announced it closed $25 million ... a venture capital firm based in Seattle ... Qiming Venture Partners . The Series B round included participation ... round in 2014, and GV (formerly Google Ventures). ...
(Date:4/20/2017)... NeuroVive Pharmaceutical AB (Nasdaq Stockholm: ... preclinical results demonstrating anti-fibrotic effects with NV556, ... (NASH), in an additional well-validated experimental NASH ... previously shown similar anti-fibrotic effects in the ... present novel data demonstrating anti-fibrotic effects of ...
Breaking Medicine Technology: